|
Patients and Family Members
Better information. Better options.
Rituximab is a valuable tool in the treatment of patients with follicular, CD20-positive NHL, but its cost and risk of side effects may make the choice to prescribe rituximab a difficult one.
Now, the PGxPredict™:RITUXIMAB test is changing the rules by providing patient-specific information about the likelihood of response to rituximab monotherapy. It’s a simple blood test that provides important information for doctors, patients, and their families.
How it Works:
- Your doctor collects a blood sample via a fingerstick and sends it to a lab for analysis.
- Test results are returned directly to your doctor within 2-5 days.
- The results designate a patient as being More Likely or Not More Likely to Respond.
- You and your doctor use the results to help determine the best treatment option.
Talk to your doctor to learn more about how the PGxPredict:RITUXIMAB test may be able to help you or someone you care about.
1-877-2-PGXHEALTH (877-274-9432)
|
